Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

noticia |

Rini B.I., Bellmunt J., Clancy J., Wang K., Niethammer A.G., Hariharan S., Escudier B.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 32:8 (752-759)

To prospectively determine the efficacy of combination therapy with temsirolimus plus bevacizumab versus interferon alfa (IFN) plus bevacizumab in metastatic renal cell carcinoma (mRCC). In a randomized, open-label, multicenter, phase III study, patients with previously untreated predominantly clear-cell mRCC were randomly assigned, stratified by prior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group, to receive the combination of either temsirolimus (25 mg intravenously, weekly) or IFN (9 MIU subcutaneously thrice weekly) with bevacizumab (10 mg/kg intravenously, every 2 weeks). The primary end point was independently assessed progression-free survival (PFS). Median PFS in patients treated with temsirolimus/bevacizumab (n = 400) versus IFN/bevacizumab (n = 391) was 9.1 and 9.3 months, respectively (hazard ratio [HR], 1.1; 95% CI, 0.9 to 1.3; P = .8). There were no significant differences in overall survival (25.8 ? 25.5 months; HR, 1.0; P = .6) or objective response rate (27.0% ? 27.4%) with temsirolimus/bevacizumab versus IFN/bevacizumab, respectively…(ver más)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)